Pediatric Sickle Cell Disease in Sudan: Complications and Management.
Journal
Anemia
ISSN: 2090-1267
Titre abrégé: Anemia
Pays: Egypt
ID NLM: 101536021
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
10
2021
accepted:
18
01
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
Sickle cell disease (SCD) is a life-threatening genetic disorder due to the formation of sickle hemoglobin molecule (HbS) that polymerizes in hypoxic conditions leading to SCD-related complications. Different approaches have been used in the management of SCD including symptomatic management, supportive management, and preventive management. To assess the management of SCD in pediatric patients in Gaafar Ibnauf Referral Hospital in Khartoum locality, Sudan. A descriptive, retrospective, hospital-based study was conducted in Gaafar Ibnauf Hospital using a data collection sheet. The study included all medical files of pediatric patients with SCD attending the hospital during the period from the first of April 2018 to the first of July 2018. The data were analyzed using descriptive statistics and the chi-square test. Out of 207 pediatric patients, 53.1% were females (mean age of 7.5 ± 3.1 years), with a 1.1 : 1 female:male ratio and low socioeconomic status. Only 4.3% of participants had health insurance. The Messeryia tribe in western Sudan had the highest prevalence of the disease among the Sudanese tribes (11.1%). Vaso-occlusive crisis (33.3%), infections (13.5%), and neurological complications (10.6%) were the most frequent complications reported during routine visits. After initiation of management, only 3.4% of pediatric patients had hemolytic crises, and 1.4% of the anemic patients had splenomegaly. 100% of patients received folic acid, 73.9% used hydroxyurea, and 69.6% underwent blood transfusion for the management of SCD. Prophylactic penicillin was prescribed for 15% of patients, and 41.1% were immunized with pneumococcal vaccine (PPSV23). Most patients had been scheduled for planned follow-up visits every 3-6 months (93.2%). Hydroxyurea and blood transfusion significantly reduced fever and vaso-occlusive crisis. The SCD treatment protocol in Gaafar Ibnauf Children's Hospital, involving preventive and symptomatic therapy, is consistent with the internationally implemented protocols for SCD management. However, immunization and prophylactic penicillin approaches are deficient.
Sections du résumé
BACKGROUND
BACKGROUND
Sickle cell disease (SCD) is a life-threatening genetic disorder due to the formation of sickle hemoglobin molecule (HbS) that polymerizes in hypoxic conditions leading to SCD-related complications. Different approaches have been used in the management of SCD including symptomatic management, supportive management, and preventive management.
OBJECTIVES
OBJECTIVE
To assess the management of SCD in pediatric patients in Gaafar Ibnauf Referral Hospital in Khartoum locality, Sudan.
METHOD
METHODS
A descriptive, retrospective, hospital-based study was conducted in Gaafar Ibnauf Hospital using a data collection sheet. The study included all medical files of pediatric patients with SCD attending the hospital during the period from the first of April 2018 to the first of July 2018. The data were analyzed using descriptive statistics and the chi-square test.
RESULTS
RESULTS
Out of 207 pediatric patients, 53.1% were females (mean age of 7.5 ± 3.1 years), with a 1.1 : 1 female:male ratio and low socioeconomic status. Only 4.3% of participants had health insurance. The Messeryia tribe in western Sudan had the highest prevalence of the disease among the Sudanese tribes (11.1%). Vaso-occlusive crisis (33.3%), infections (13.5%), and neurological complications (10.6%) were the most frequent complications reported during routine visits. After initiation of management, only 3.4% of pediatric patients had hemolytic crises, and 1.4% of the anemic patients had splenomegaly. 100% of patients received folic acid, 73.9% used hydroxyurea, and 69.6% underwent blood transfusion for the management of SCD. Prophylactic penicillin was prescribed for 15% of patients, and 41.1% were immunized with pneumococcal vaccine (PPSV23). Most patients had been scheduled for planned follow-up visits every 3-6 months (93.2%). Hydroxyurea and blood transfusion significantly reduced fever and vaso-occlusive crisis.
CONCLUSION
CONCLUSIONS
The SCD treatment protocol in Gaafar Ibnauf Children's Hospital, involving preventive and symptomatic therapy, is consistent with the internationally implemented protocols for SCD management. However, immunization and prophylactic penicillin approaches are deficient.
Identifiants
pubmed: 35198244
doi: 10.1155/2022/3058012
pmc: PMC8860554
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3058012Informations de copyright
Copyright © 2022 Meysaa Talha et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ann Intern Med. 2021 Jan;174(1):ITC1-ITC16
pubmed: 33428443
Oman Med J. 2012 Mar;27(2):121-3
pubmed: 22496936
MMWR Recomm Rep. 2010 Dec 10;59(RR-11):1-18
pubmed: 21150868
Expert Rev Hematol. 2018 Jan;11(1):45-55
pubmed: 29207881
Rev Prat. 2014 Oct;64(8):1114-9
pubmed: 25510139
Int J Qual Health Care. 2004 Jun;16(3):245-51
pubmed: 15150156
Br J Haematol. 2017 Jun;177(6):938-946
pubmed: 28493472
N Engl J Med. 2020 Jun 25;382(26):2524-2533
pubmed: 32579813
Neurology. 2017 Oct 3;89(14):1516-1524
pubmed: 28864674
Hematol Rep. 2010 Jan 26;2(1):e2
pubmed: 22184515
Trop Med Int Health. 2016 May;21(5):642-53
pubmed: 27028397
Cochrane Database Syst Rev. 2021 Mar 8;3:CD003427
pubmed: 33724440
Pan Afr Med J. 2014 May 03;18:13
pubmed: 25360197
Blood Adv. 2020 Apr 28;4(8):1554-1588
pubmed: 32298430
P T. 2008 Apr;33(4):238-43
pubmed: 19750169
Arch Dis Child. 2015 Jan;100(1):48-53
pubmed: 25239949
Cold Spring Harb Perspect Med. 2013 Oct 01;3(10):a011783
pubmed: 23813607
Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405
pubmed: 22099364
Clin Hemorheol Microcirc. 2018;68(2-3):105-128
pubmed: 29614627
Int J Pediatr Adolesc Med. 2021 Dec;8(4):236-238
pubmed: 34401448
Cureus. 2021 Jan 3;13(1):e12440
pubmed: 33552759
Pharmacotherapy. 2000 Jan;20(1):110-7
pubmed: 10641985
Anemia. 2015;2015:791498
pubmed: 25667774
Trends Cardiovasc Med. 2021 Apr;31(3):187-193
pubmed: 32139143
Blood Adv. 2020 Jun 23;4(12):2656-2701
pubmed: 32559294
Am Fam Physician. 2015 Dec 15;92(12):1069-76
pubmed: 26760593
BMC Res Notes. 2019 Oct 16;12(1):659
pubmed: 31619285
Lancet Haematol. 2019 Aug;6(8):e393-e394
pubmed: 31227475